Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CX-072 + Ipilimumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CX-072||CX072|CX 072|Pacmilimab||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 69||CX-072 (Pacmilimab) is a prodrug consisting of a monoclonal antibody to PD-L1 (CD274) and a masking peptide that is cleaved by proteases specific to tumor cells (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3072-3072, PMID: 32681519).|
|Ipilimumab||Yervoy||BMS-734016||CTLA4 Antibody 18 Immune Checkpoint Inhibitor 98||Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||CX-072 + Ipilimumab||Phase II||Actionable||In a Phase II trial (PROCLAIM-CX-072), CX-072 and Yervoy (ipilimumab) combination treatment demonstrated acceptable safety, and resulted in a disease control rate of 37% (10/27, 1 complete response, 4 partial responses) in patients with advanced solid tumors (J Clin Oncol 38: 2020 (suppl; abstr 3005); NCT03993379).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03013491||Phase II||CX-072 + Ipilimumab CX-072 + Vemurafenib CX-072||A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas||Active, not recruiting||USA||4|